Sirolimus for calcineurin inhibitors in organ transplantation: contra (Q37779484)

23 August 2017

1 reference

title

Sirolimus for calcineurin inhibitors in organ transplantation: contra (English)

1 reference

23 August 2017

main subject

organ transplantation

1 reference

1 reference

3

1 reference

23 August 2017

2

Piero Ruggenenti

1 reference

23 August 2017

1

Paolo Cravedi

1 reference

23 August 2017

language of work or name

English

0 references

publication date

11 August 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

78

1 reference

23 August 2017

issue

11

1 reference

23 August 2017

page(s)

1068-1074

1 reference

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Sirolimus: its discovery, biological properties, and mechanism of action

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Reduced exposure to calcineurin inhibitors in renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Sirolimus: defining nephrotoxicity in the renal transplant recipient

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

mTOR regulates memory CD8 T-cell differentiation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Immunosuppression: evolution in practice and trends, 1994-2004.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Controlling the generation and function of human CD8+ memory T cells in vitro with immunosuppressants

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Prospective observational study of sirolimus as primary immunosuppression after renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Immunology: A metabolic switch to memory.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

The multifunctional role of mTOR in innate immunity: implications for transplant immunity.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Transplantation: time to rethink immunosuppression by mTOR inhibitors?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Immunoregulatory functions of mTOR inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Proteinuria following a switch from calcineurin inhibitors to sirolimus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

High sirolimus levels may induce focal segmental glomerulosclerosis de novo

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Sirolimus is associated with new-onset diabetes in kidney transplant recipients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Recovery from diabetes in mice by beta cell regeneration

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Sirolimus interferes with iron homeostasis in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Management of side effects of sirolimus therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Sirolimus may reduce fertility in male renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

High prevalence of ovarian cysts in premenopausal women receiving sirolimus and tacrolimus after clinical islet transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Alterations of the female reproductive system in recipients of islet grafts

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Sirolimus-associated diffuse alveolar hemorrhage

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Sirolimus to replace calcineurin inhibitors? Too early yet.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Rapamycin: could it enhance vaccine efficacy?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Kidney Transplantation With Sirolimus and Mycophenolate Mofetil???Based Immunosuppression: 5-Year Results of a Randomized Prospective Trial Compared to Calcineurin Inhibitor Drugs

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.268

7 January 2021

Identifiers

DOI

10.1038/KI.2010.268

1 reference

23 August 2017

1 reference